Q2 2026 saw 44% revenue growth to $335M, driven by strong oncology, biopharma, and screening performance. Major milestones included FDA approvals, Shield's inclusion in ACS guidelines, and UnitedHealth coverage, expanding access to 70M lives. Full-year guidance was raised on robust demand and operational efficiency.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.